Vivo Capital announced the final closing of its Vivo Capital Fund IX LP with a fund raise of $1.43 billion from existing and new global institutional investors.
The firm plans to invest in and build innovative and rapidly growing healthcare and life science companies.
The Palo Alto firm has raised more than $4 billion in capital since its 1996 inception and has backed more than 200 private and public portfolio companies.
According to the firm’s announcement on the new fund, it said that its unique global capabilities enable Vivo to help . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.